Price Action to Note: Could Amarin Corporation plc (ADR) See a Reversal After This Very Strong Session?

Price Action to Note: Could Amarin Corporation plc (ADR) See a Reversal After This Very Strong Session?

The stock of Amarin Corporation plc (ADR) (NASDAQ:AMRN) is a huge mover today! About 2.98 million shares traded hands or 4.20% up from the average. Amarin Corporation plc (ADR) (NASDAQ:AMRN) has risen 93.18% since April 14, 2016 and is uptrending. It has outperformed by 88.50% the S&P500.
The move comes after 7 months positive chart setup for the $990.60 million company. It was reported on Nov, 16 by Barchart.com. We have $5.56 PT which if reached, will make NASDAQ:AMRN worth $564.64M more.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) Ratings Coverage

Out of 3 analysts covering Amarin Corp (NASDAQ:AMRN), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Amarin Corp has been the topic of 3 analyst reports since May 12, 2016 according to StockzIntelligence Inc. On Wednesday, October 5 the stock rating was initiated by Cantor Fitzgerald with “Buy”. On Wednesday, October 19 the stock rating was initiated by Citigroup with “Buy”. The rating was initiated by Jefferies on Thursday, May 12 with “Buy”.

According to Zacks Investment Research, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.”

Insitutional Activity: The institutional sentiment increased to 1.04 in Q2 2016. Its up 0.41, from 0.63 in 2016Q1. The ratio improved, as 9 funds sold all Amarin Corporation plc (ADR) shares owned while 17 reduced positions. 7 funds bought stakes while 20 increased positions. They now own 30.07 million shares or 19.93% less from 37.56 million shares in 2016Q1.
Kcg Hldg Inc accumulated 73,026 shares or 0% of the stock. Clearbridge Invs Ltd Limited Liability Company holds 0% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 423 shares. Blackrock Fund Advsr last reported 2.26 million shares in the company. Lpl Llc last reported 0% of its portfolio in the stock. First Republic Investment Mngmt Inc accumulated 86,500 shares or 0% of the stock. Royal Bancorp Of Canada has 0% invested in the company for 100 shares. Great Point Ptnrs Ltd Liability Com last reported 0% of its portfolio in the stock. Finance Architects Incorporated last reported 0.01% of its portfolio in the stock. Reilly Fincl Limited Co accumulated 11,000 shares or 0% of the stock. Citigroup has 23,207 shares for 0% of their US portfolio. Apriem Advsr holds 0.01% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 7,618 shares. Broadfin Capital Ltd Llc reported 4.68M shares or 0.98% of all its holdings. Moreover, Pnc Fincl Serv has 0% invested in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 25,600 shares. J Goldman & Commerce Limited Partnership has 420,000 shares for 0.05% of their US portfolio. Orbimed Advisors Limited Liability Co owns 350,000 shares or 0.01% of their US portfolio.

Another recent and important Amarin Corporation plc (ADR) (NASDAQ:AMRN) news was published by Fool.com which published an article titled: “Why Amarin Corporation plc (ADR) is Moving Higher Today” on August 07, 2015.

AMRN Company Profile

Amarin Corporation plc, incorporated on March 1, 1989, is a biopharmaceutical firm with activities in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Firm operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Firm markets Vascepa in the United States through its sales force of approximately 150 sales professionals, including sales representatives and their managers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment